Yüklüyor......
We do still transplant CML, don’t we?
The remarkable clinical activity of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has transformed patient outcome. Consequently, allogeneic stem cell transplantation (allo-SCT) is no longer the only treatment modality with the ability to deliver long-term survival. In contrast...
Kaydedildi:
| Yayımlandı: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6246013/ https://ncbi.nlm.nih.gov/pubmed/30504307 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|